Stock Price Prediction

ONCY stock has a bullish outlook with a price target of $5.00, as reiterated by Maxim Group and HC Wainwright. This optimism is driven by strong Phase 2 BRACELET-1 study results, showing significant survival benefits for metastatic breast cancer patients treated with pelareorep. Additionally, the company is advancing toward a registration-directed study, enhancing its potential for FDA approval and commercial success.

ONCY stock is bearish in the short term, trading at $0.95, down 7.77% over six months despite strong Phase 2 clinical results. The stock's inability to sustain momentum reflects market skepticism about near-term catalysts, even with a $5 price target from analysts. Continued underperformance suggests limited upside until further regulatory or clinical milestones are achieved.